Silvia Marfil Verchili
Silvia Marfil has been a clinical analyst since 1992. Following training at the Bonanova Institute of Barcelona, she undertook a work placement at the Hospital de Mar Medical Research Institute (IMIM), after which she was employed by Prodesfarma to work in the immunology departament of the Germans Trias i Pujol University Hospital in Badalona.
More recently she joined IrsiCaixa, where she undertakes tasks in suport of research in the group headed by Dr. Julià Blanco and also works in Albajuna Therapeutics, an IrsiCaixa spin-off. She collaborates with the Xplore Health educational programme, preparing the workshop on investigating the HIV vaccine.
Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2.
Impact of chemotherapy and/or immunotherapy on neutralizing antibody response to SARS-CoV-2 mRNA-1237 vaccine in patients with solid tumors.
Contribution of the HIV-1 Envelope Glycoprotein to AIDS Pathogenesis and Clinical Progression.
Glucocorticoids' treatment impairs the medium-term immunogenic response to SARS-CoV-2 mRNA vaccines in Systemic Lupus Erythematosus patients.
Efficacy of SARS-CoV-2 vaccination in patients with monoclonal gammopathies: A cross sectional study.